Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

• Ashoka Buildcon Shares Slump 3% Despite Securing Rs 410 Crore Project 
• Zydus Lifesciences Gets USFDA Nod; Stock Trades Flat
• Religare Enterprises Shares Slumped 6% on Demerger Plan 
• Natco Pharma Gets CDSCO Nod; Shares Rally 12.5%
• Lodha Developers Buys Solidrise for Rs 300 Cr; Shares Jump 1.5%

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.